Overview
Floreo offers a subscription VR platform with a library of about 200 research-informed lessons that teach social, communication, behavioral, and life skills to neurodiverse individuals, including those with autism. The product combines a learning VR experience with a coaching device, accessed through the Floreo Portal, enabling guided practice in immersive, real-world–style scenarios for use in therapy, education, and home settings. What sets Floreo apart is its substantial, science-backed lesson library and a coaching-enabled delivery model that works across clinical, classroom, and family contexts, with partnerships and recognition from groups like NIMH. Its goal is to provide accessible, evidence-based immersive training that helps neurodiverse individuals develop essential skills and improve everyday functioning and independence.
Work here?Claim your company
Simplify's take
What believers are saying
- North Carolina approved Medicaid waiver reimbursement on September 1, 2026, expanding Floreo's paid access.
- Floreo added Tennessee, New York, and Wisconsin reimbursement, proving state-level payer adoption.
- The April 2026 pivotal trial and 17-site rollout support commercialization with Cortica and ABA providers.
What critics are saying
- FDA De Novo review for FloreoRx creates binary 2026 regulatory risk; rejection crushes the flagship product.
- Reimbursement remains fragmented; 2027 CPT 0770T economics determine whether payers fund Floreo at scale.
- Meta, Apple, and enterprise VR vendors can commoditize immersive training, squeezing Floreo's category and margins.
What makes Floreo unique
- Floreo owns a purpose-built VR curriculum for autism, ADHD, and developmental delays, not generic edtech.
- Its FloreoRx De Novo targets the first FDA-authorized VR therapy for social communication in autism.
- Clinicians and parents use coached, in-home lessons across nearly 200 scenarios, expanding deployment beyond clinics.
Help us improve and share your feedback! Did you find this helpful?